Dasatinib Shows Promise for Pediatric CML, ALL Patients

A phase I study of dasatinib in children and adolescents with chronic myeloid leukemia (CML) and other malignancies determined dosing for further studies and suggested the drug is well tolerated and effective in these patients.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news